Karim Roksana, Mack Wendy J, Kono Naoko, Tien Phyllis C, Anastos Kathryn, Lazar Jason, Young Mary, Desai Seema, Golub Elizabeth T, Kaplan Robert C, Hodis Howard N, Kovacs Andrea
*Maternal, Child and Adolescent Center for Infectious Disease and Virology, Department of Pediatrics, University of Southern California, Los Angeles, CA; †Department of Preventive Medicine, University of Southern California, Los Angeles, CA; ‡Atherosclerosis Research Unit, University of Southern California, Los Angeles, CA; §Department of Medicine, University of California, San Francisco, San Francisco, CA; ‖Medical Service, Department of Veterans Affairs, University of California, San Francisco, San Francisco, CA; ¶Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY; #Division of Cardiovascular Medicine, State University of New York Downstate Medical Center, Brooklyn, NY; **Georgetown University Medical Center, Georgetown University, Washington, DC; ††Departments of Medicine, Stroger Hospital and Rush University, Chicago, IL; ‡‡Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and §§Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.
J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):349-56. doi: 10.1097/QAI.0000000000000311.
T-cell activation is a major pathway driving HIV disease progression. Little is known regarding the impact of T-cell activation on HIV-associated atherosclerosis and cardiovascular disease, a common comorbidity in HIV infection. We hypothesized that T-cell activation will predict vascular stiffness, a measure of subclinical atherosclerosis.
Linear regression models evaluated the covariate-adjusted association of T-cell activation with vascular stiffness.
CD38 and HLA-DR expression on CD4⁺ and CD8⁺ T cells was assessed by flow cytometry among 59 HIV-negative and 376 HIV-infected (185 hepatitis C coinfected) women in the Women's Interagency HIV Study. T-cell activation was defined by CD8⁺CD38⁺DR+ and CD4⁺CD3⁺8DR+. Multiple activation assessments over 6.5 years were averaged. In 140 women, T-cell activation was measured before and after highly active antiretroviral therapy (HAART) initiation. Carotid artery ultrasounds were completed a median of 6.5 years after last measurement of T-cell activation and carotid artery stiffness including distensibility and elasticity were calculated.
Percentages of CD4⁺ and CD8⁺ T-cell activation were significantly higher in HIV- infected compared with HIV-negative women. Among HIV-negative women, T-cell activation was not associated with carotid artery stiffness. Among HIV-infected women, higher CD4⁺ T-cell activation levels significantly predicted increased arterial stiffness independent of CD4⁺ cell count and HIV RNA. The association was stronger among HIV/hepatitis C-coinfected women compared with HIV-monoinfected women; however, the difference was not statistically significant (P for interaction >0.05). Pre- and post-HAART levels of CD4⁺ T-cell activation significantly predicted carotid artery stiffness.
Persistent T-cell activation, even after HAART initiation, can contribute to structural and/or functional vascular damage accelerating atherogenesis in HIV infection. These results need to be confirmed in a longitudinal prospective study.
T细胞活化是推动HIV疾病进展的主要途径。关于T细胞活化对HIV相关动脉粥样硬化和心血管疾病(HIV感染中常见的合并症)的影响,我们所知甚少。我们假设T细胞活化将预示血管硬度,这是亚临床动脉粥样硬化的一项指标。
线性回归模型评估了T细胞活化与血管硬度的协变量调整关联。
在女性机构间HIV研究中,通过流式细胞术评估了59名HIV阴性和376名HIV感染(185名合并丙型肝炎感染)女性的CD4⁺和CD8⁺T细胞上CD38和HLA - DR的表达。T细胞活化由CD8⁺CD38⁺DR⁺和CD4⁺CD3⁺8DR⁺定义。对6.5年期间的多次活化评估进行平均。在140名女性中,在开始高效抗逆转录病毒治疗(HAART)之前和之后测量T细胞活化。在最后一次测量T细胞活化后中位数6.5年完成颈动脉超声检查,并计算包括扩张性和弹性在内的颈动脉硬度。
与HIV阴性女性相比,HIV感染女性中CD4⁺和CD8⁺T细胞活化百分比显著更高。在HIV阴性女性中,T细胞活化与颈动脉硬度无关。在HIV感染女性中,较高的CD4⁺T细胞活化水平显著预示动脉硬度增加,独立于CD4⁺细胞计数和HIV RNA。与单纯HIV感染女性相比,HIV/丙型肝炎合并感染女性中的关联更强;然而,差异无统计学意义(交互作用P>0.05)。HAART治疗前后的CD4⁺T细胞活化水平显著预示颈动脉硬度。
即使在开始HAART治疗后,持续的T细胞活化也可能导致血管结构和/或功能损害,加速HIV感染中的动脉粥样硬化形成。这些结果需要在纵向前瞻性研究中得到证实。